Friday July 10, 2020 16:35

Heathcare Press Release : 15 Jun 2020

Investigational, Once-weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-daily Heathcare—15 Jun 20

Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the trial, adults with type 2 diabetes randomised to once-weekly insulin icodec achieved similar blood sugar

Switching to Ozempic(R) from another GLP-1 RA significantly reduced blood sugar and weight in Heathcare—15 Jun 20

- A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) were significantly more likely to reach their blood sugar goals and lose